The Carlsbad, CA-based contract research organization (CRO) Synteract has acquired the international CRO Munich-based company Harrison Clinical Research.
The company will now act globally as SynteractHCR, with offices in Western and Eastern Europe, Israel, Russia, South America, and the U.S. The new company says it will be a top-tier service provider with the scale to support large, late-stage programs across multiple clinical areas, including oncology, the central nervous system, infectious diseases, endocrinology, cardiovascular diseases, and respiratory disorders.
In a statement, SynteractHCR says it plans to maintain a strong connection with “emerging to midsize biopharmaceutical companies through which a consultative approach and strong clinical development expertise forms the foundation of its customer relationships.”
“Our longstanding drug development expertise allows us to form a new global leader with enhanced scale and therapeutic breadth, but with the personal approach that we have always taken to working with clients,” said CEO Wendel Barr. “We will provide a continuity of service to allow us to work with clients throughout the entire development life cycle, from emerging products through post-marketing, and will bring technology efficiencies to the company that will help to take time and cost out of drug development.”
